PARD6B

Across TCGA pan-cancer cohorts, PARD6B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PARD6B data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PARD6B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PARD6B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where PARD6B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.985	0.237	.017	8	view →
LUAD	OS	Quartile	III,IV	1.000	0.396	.043	4	view →
PDAC	OS	Quartile	II,III,IV	0.649	0.445	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PARD6B–CCRCC (OS)

Open the CCRCC breakdown →